lastampa.itil secoloxix








Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease

Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease

Coronary Artery DiseaseLate-breaking data published and presented today confirm that the non-invasive HeartFlow® FFRct Analysis enables physicians to effectively differentiate patients in need of coronary stenting or bypass surgery from those who can be managed with medications alone.

The ADVANCE Registry was published in the European Heart Journal (EHJ) and the Aarhus University Hospital experience was published in the Journal of the American College of Cardiology (JACC). Both studies were presented during the late-breaking science session today at the European Society of Cardiology (ESC) conference.In these studies, the HeartFlow Analysis changed physician management of patients and enabled physicians to determine more efficiently which patients required invasive management and which did not. The HeartFlow Analysis identified a set of patients at very low risk of adverse outcomes when undergoing medical therapy, and a set whose risk was reduced when undergoing invasive management.

The ADVANCE Registry included more than 5,000 patients in the U.S., Japan, Europe and Canada. The Aarhus University Hospital experience included more than 3,600 patients in Denmark who were followed for an average of two years. “These studies confirm the role of the HeartFlow Analysis in identifying disease that other tests may miss, and in providing reassurance to patients and doctors that some blockages are not in need of invasive management,” said Campbell Rogers, MD, FACC, chief medical officer, HeartFlow.

In primo piano